-
Gilead’s Biktarvy receives FDA OK for expanded indication
Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance. -
Viatris, Idorsia enter into global R&D collaboration
The R&D collaboration includes selatogrel, a cardiology medication, and cenerimod, a drug for the treatment of lupus.